Kymera Therapeutics, Inc. (KYMR) Up 28% in 3M, Analysts See Further Upside

Kymera Therapeutics, Inc. (NASDAQ:KYMR) is among the 14 best booming stocks to buy right now. Its shares have gained over 28% in the last three months, with Wall Street anticipating a further uptick of nearly 60%, as of the close of business on January 12.

However, on January 6, Wolfe Research downgraded the stock to Peer Perform from Outperform, and according to a report on TipRanks, the firm also removed its $92 price target for the company’s shares.

In a research note to investors, Wolfe Research described the stock as ‘a poor investment in 2026’, citing a lack of catalysts that could drive an upside and valuation concerns about the stock among investors. However, the firm’s analyst still considers Kymera Therapeutics, Inc. (NASDAQ:KYMR) a good investment over the long term.

On the same day, BTIG reiterated its Buy rating on the stock with a share price target of $138. Earlier on January 5, Citigroup also kept its Buy rating and maintained an earlier price target of $110 on its shares.

In December, the company announced that it had received Fast Track designation from the FDA for its KT-621 oral STAT6 degrader to treat atopic dermatitis. This followed promising results from the BroADen Phase 1b clinical trial that demonstrated the potential of treating various Type 2 inflammatory diseases across metrics through a once-daily intake.

Kymera Therapeutics, Inc. (NASDAQ:KYMR) is a biopharmaceutical company developing protein degradation therapies to address critical medical problems.

READ NEXT: 14 Best S&P 500 Stocks to Buy Now and 11 Most Oversold S&P 500 Stocks Heading into 2026

Disclosure: None.